You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Tetrindole mesylate
Tetrindole mesylate is a novel antidepressant, a selective inhibitor of MAO-A.
Technical Data for Tetrindole mesylate
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Tetrindole mesylate
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Tetrindole mesylate
The following data is based on the product molecular weight 390.54. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.56 mL||12.8 mL||25.61 mL|
|5 mM||0.51 mL||2.56 mL||5.12 mL|
|10 mM||0.26 mL||1.28 mL||2.56 mL|
|50 mM||0.05 mL||0.26 mL||0.51 mL|
Product Datasheets for Tetrindole mesylate
References for Tetrindole mesylate
References are publications that support the biological activity of the product.
Bos et al (1995) Resolution, EPC-syntheses, absolute stereochemistry, and pharmacology of the (S)-(+)- and (R)-(-)-isomers of the MAO-A inhibitor tetrindole hydrochloride. Arch.Pharm. (Wenheim) 328 619 PMID: 7492268
Korshunov et al (2000) Hemodynamic effects of tetrindol in alert normotensive mice and rats after blockade of nitric oxide synthesis. Bull.Exp.Biol.Med. 130 777 PMID: 11177242
Medvedev et al (1994) Monoamine oxidase inhibition by novel antidepressant tetrindole. Biochem.Pharmacol. 47 303 PMID: 8304974
If you know of a relevant reference for Tetrindole mesylate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Tetrindole mesylate, Tetrindole mesylate supplier, MAO-A, inhibitors, inhibits, Monoamine, Oxygenases, Oxidases, Oxidase, Adrenergic, Related, Compounds, Dopaminergic-Related, 5-HT-Related, 5-HT3, Receptors, 0723, Tocris Bioscience
1 Citation for Tetrindole mesylate
Citations are publications that use Tocris products. Selected citations for Tetrindole mesylate include:
Ulferts et al (2016) Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C. Antimicrob Agents Chemother 60 2627 PMID: 26856848
Do you know of a great paper that uses Tetrindole mesylate from Tocris? Please let us know.
Reviews for Tetrindole mesylate
There are currently no reviews for this product. Be the first to review Tetrindole mesylate and earn rewards!
Have you used Tetrindole mesylate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.